MAAT INDEX

CLAIM #18616 · CVS Health Corp (CVS) · 2025Q4 earnings call · Feb 10, 2026 · due Dec 31, 2026

We expect to drive further improvement in our leverage this year as we continue to improve enterprise earnings.

Brian O. Newman · CFO

PENDING
graded after results covering Dec 31, 2026 are reported

How to check this claim

Look at: Company-reported leverage ratio (debt/EBITDA) as disclosed at year-end

It came true if: Year-end 2026 leverage ratio less than approximately 4x (year-end 2025 level)

Where: Company earnings release / 10-K disclosure of leverage ratio (Q4 2026 call or filing)

In context

erformance as durable, which led us to revise our long-term annual earnings outlook for this business to at least flat going forward. Shifting now to cash flow and the balance sheet. In 2025, we generated cash flows from operations of approximately $10.6 billion. This strong result includes the receipt of certain payments at the end of the year that were previously expected in early 2026, as well as continued focus on working capital efficiencies. We distributed over $3 billion in dividends to our shareholders in 2025 and ended the quarter with approximately $2.8 billion of cash at the parent and unrestricted subsidiaries. Our leverage ratio as of year-end 2025 was approximately 4x, a meaningful improvement from the prior year, primarily driven by our strong financial performance in 2025. We expect to drive further improvement in our leverage this year as we continue to improve enterprise earnings. Shifting now to our outlook for 2026. As David and I both discussed at our Investor Day in December, we are focused on delivering on our financial commitments. Our guidance philosophy is predicated on reflecting thoughtful and credible targets while simultaneously striving to identify and execute on opportunities to deliver outperformance. It also includes our commitment to clear communication. These are the principles we used when issuing our initial 2026 guidance at the end of last year and are what you can expect as we move forward. Today, we are reaffirming our guidance for full year 2026 revenue of at least $400 billion, as well as our expectation for full year 2026 adjusted EPS in a range of $7 to $7.20. We are encouraged by the strength of our results as we closed out 2025 and by o

Verify independently

SEC filings for CVS · Claim quote is verbatim from the 2025Q4 earnings call.